Focus: Locus Biosciences is a public-stage biotechnology company developing CRISPR-engineered bacteriophage therapeutics, a novel modality targeting infectious diseases with initial focus on urinary tract infections.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Locus represents a high-risk, high-innovation opportunity suitable only for scientists/engineers comfortable with pre-revenue biotech volatility and interested in bacteriophage biology.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Locus Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Locus Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles